(Q35826159)

English

The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis

scientific article published in June 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis (English)

1 reference

Europe PubMed Central

10 August 2017

hemodialysis patient

1 reference

based on heuristic

inferred from title

8

object named as

Tadao Akizawa

1 reference

Europe PubMed Central

10 August 2017

author name string

Naro Ohashi

1

1 reference

Europe PubMed Central

10 August 2017

Toshihiko Uematsu

2

1 reference

Europe PubMed Central

10 August 2017

Satoru Nagashima

3

1 reference

Europe PubMed Central

10 August 2017

Mitsutaka Kanamaru

4

1 reference

Europe PubMed Central

10 August 2017

Akashi Togawa

5

1 reference

Europe PubMed Central

10 August 2017

Akira Hishida

6

1 reference

Europe PubMed Central

10 August 2017

Eiji Uchida

7

1 reference

Europe PubMed Central

10 August 2017

Shozo Koshikawa

9

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

10 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

10 August 2017

57

1 reference

Europe PubMed Central

10 August 2017

6

1 reference

Europe PubMed Central

10 August 2017

726-734

1 reference

Europe PubMed Central

10 August 2017

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

What is the optimal regimen for vitamin D?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Pathogenesis of secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Effects of excess PTH on nonclassical target organs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Who gets renal bone disease before beginning dialysis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

11 July 2018

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02088.X

21 January 2018

Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02088.X

21 January 2018

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2004.02088.X

21 January 2018

Recent developments in the management of secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

24 September 2018

Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

24 September 2018

Are we mismanaging calcium and phosphate metabolism in renal failure?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

24 September 2018

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884513

24 September 2018

Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-dihydroxyvitamin D

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The spectrum of bone disease in end-stage renal failure--an evolving disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NPS R-568 halts or reverses osteitis fibrosa in uremic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/15151518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2004.02088.X

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35826159&oldid=2165232883"